Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,268 GBX | +0.16% | +3.59% | +6.30% |
03:38pm | AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder | MT |
10:50am | ASTRAZENECA : JP Morgan reaffirms its Buy rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.30% | 215B | |
+27.74% | 659B | |
+27.68% | 557B | |
-4.19% | 359B | |
+16.47% | 322B | |
+9.51% | 297B | |
+4.80% | 210B | |
-6.05% | 200B | |
-8.87% | 149B | |
-4.81% | 146B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : SVB Leerink Adjusts AstraZeneca's PT to $73 from $71, Keeps Outperform Rating